COMPOUND PROFILE / PEPTIDES & ANALOGUES
Glepaglutide.
Research draftGlepaglutide is a long-acting GLP-2 analogue investigated for short bowel syndrome.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Glepaglutide is a long-acting GLP-2 analogue investigated for short bowel syndrome.
Mechanism
It promotes intestinal adaptation and absorption-related responses.
Human research
Randomised phase 2 and phase 3 research measured reductions in parenteral support; findings are specific to short bowel syndrome.
Preclinical & other research
Intestinal models support the adaptation rationale.
Safety & unknowns
Fluid balance, gastrointestinal effects and relevant disease monitoring matter.
Regulatory status
Trial evidence and any local authorisation must be assessed separately.
Reported use & evidence
The supplied Glepaglutide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.